Predicted to have phospholipid binding activity. Predicted to be involved in several processes, including cytosolic lipolysis; lipid droplet formation; and regulation of lipid metabolic process. Predicted to localize to integral component of endoplasmic reticulum membrane and lipid droplet. Used to study azoospermia. Human ortholog(s) of this gene implicated in congenital generalized lipodystrophy type 2; hereditary spastic paraplegia; hereditary spastic paraplegia 17; and lipodystrophy. Orthologous to human BSCL2 (BSCL2 lipid droplet biogenesis associated, seipin); INTERACTS WITH (+)-schisandrin B; 6-propyl-2-thiouracil; bisphenol A.
[schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Aphidicolin results in increased expression of BSCL2 mRNA], [schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Cisplatin results in increased expression of BSCL2 mRNA]
[7-hydroxystaurosporine results in decreased activity of [CHEK1 protein co-treated with BSCL2 protein]] inhibits the reaction [Aphidicolin results in increased expression of CHEK2 mRNA], [schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Aphidicolin results in increased expression of BSCL2 mRNA]
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA
[7-hydroxystaurosporine results in decreased activity of [CHEK1 protein co-treated with BSCL2 protein]] inhibits the reaction [Cisplatin results in increased expression of CHEK2 mRNA], [schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Cisplatin results in increased expression of BSCL2 mRNA]
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin